The PE Ratio as of December 2024 (TTM) for Trevi Therapeutics, Inc. (TRVI) is -9.09

According to Trevi Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -9.09. This represents a change of 50.18% compared to the average of -6.05 of the last 4 quarters.

Trevi Therapeutics, Inc. (TRVI) Historical PE Ratio (quarterly & annually)

How has TRVI PE Ratio performed in the past?

The mean historical PE Ratio of Trevi Therapeutics, Inc. over the last ten years is -4.10. The current -9.09 PE Ratio has changed 22.06% with respect to the historical average. Over the past ten years (40 quarters), TRVI's PE Ratio was at its highest in in the December 2017 quarter at -0.25. The PE Ratio was at its lowest in in the December 2022 quarter at -8.60.

Trevi Therapeutics, Inc. (TRVI) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Trevi Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Trevi Therapeutics, Inc. (TRVI) Average PE Ratio

How has TRVI PE Ratio performed in the past?

The current PE Ratio of Trevi Therapeutics, Inc. (TRVI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Trevi Therapeutics, Inc. (TRVI) PE Ratio vs. Peers

How is TRVI’s PE Ratio compared to its peers?

Trevi Therapeutics, Inc.’s PE Ratio is less than aTyr Pharma, Inc. (-2.33), less than Cue Biopharma, Inc. (-1.16), less than AN2 Therapeutics, Inc. (-0.67), less than BioAtla, Inc. (-0.37), less than Spero Therapeutics, Inc. (17.30), less than Bolt Biotherapeutics, Inc. (-0.30), greater than Coherus BioSciences, Inc. (-376.35), greater than Gracell Biotechnologies Inc. (-29.26), less than Neoleukin Therapeutics, Inc. (-5.86), less than Foghorn Therapeutics Inc. (-3.45), less than C4 Therapeutics, Inc. (-2.55), greater than Cyteir Therapeutics, Inc. (-9.12), less than Prelude Therapeutics Incorporated (-0.69), less than Rezolute, Inc. (-4.44), less than Lyra Therapeutics, Inc. (-0.12), less than SQZ Biotechnologies Company (-0.02), less than Protara Therapeutics, Inc. (-2.75), less than TRACON Pharmaceuticals, Inc. (0.02), less than Seer, Inc. (-1.64), less than ORIC Pharmaceuticals, Inc. (-4.82), less than Anebulo Pharmaceuticals, Inc. (-5.30), less than Cullinan Oncology, Inc. (-4.99),

Build a custom stock screener for Trevi Therapeutics, Inc. (TRVI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Trevi Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Trevi Therapeutics, Inc. (TRVI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Trevi Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.